BioCentury
ARTICLE | Financial News

CanSino could get $598M valuation in Hong Kong IPO

March 22, 2019 4:57 PM UTC

By Hongjiang Li, Staff Writer

CanSino would be valued at HK$4.7 billion (US$597.6 million) if the prerevenue vaccine company prices its Hong Kong IPO at the midpoint of the range it proposed Monday...

BCIQ Company Profiles

CanSino Biologics Inc.